CAJ | 학술논문

系统性红斑狼疮是一种侵犯身体多脏器的典型的自体免疫疾病，对人体危害极大。严重肾脏受累的系统性红斑狼疮患者如果不给予适当治疗会进展到末期肾病，甚至死亡。系统性红斑狼疮的治疗是现今研究关注的热点。现有的激素治疗由于副作用以及对病程恶化无显著改善而限制了其临床应用。生物技术药物因其良好的靶向性为治疗系统性红斑狼疮提供了新的思路，其安全性和有效性已在临床试验中证明。本文对生物技术药物用于治疗系统性红斑狼疮的研究作一综述。
계통성홍반랑창시일충침범신체다장기적전형적자체면역질병，대인체위해겁대。엄중신장수루적계통성홍반랑창환자여과불급여괄당치료회진전도말기신병，심지사망。계통성홍반랑창적치료시현금연구관주적열점。현유적격소치료유우부작용이급대병정악화무현저개선이한제료기림상응용。생물기술약물인기량호적파향성위치료계통성홍반랑창제공료신적사로，기안전성화유효성이재림상시험중증명。본문대생물기술약물용우치료계통성홍반랑창적연구작일종술。
This paper aims to review the current development of therapies of systemic lupus erythe-matosus (SLE) based on biological agents. The conventional immunosuppressive therapies such as azathio-prine, cyclophosphamide and ormethotrexate reduce disease activity and improves the patients' general health conditions. However, these treatments have possible side effects. According to domestic and foreign literatures, new developed biological agents against SLE are summarized as follows: biologic agents that block B-cell activation; biologic agents that induce tolerance; biologic agents that induce antibody targeting IFN; biologic agents that target anti-dsDNA, Antigen-Based Heteropolymer. From these results it could be concluded that biological agents open a new path for the treatment of SLE.